Pan-serotype dengue virus inhibitor JNJ-A07 targets NS4A-2K-NS4B interaction with NS2B/NS3 and blocks replication organelle formation.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
19 Jul 2024
Historique:
received: 26 06 2023
accepted: 05 07 2024
medline: 20 7 2024
pubmed: 20 7 2024
entrez: 19 7 2024
Statut: epublish

Résumé

Dengue fever represents a significant medical and socio-economic burden in (sub)tropical regions, yet antivirals for treatment or prophylaxis are lacking. JNJ-A07 was described as highly active against the different genotypes within each serotype of the disease-causing dengue virus (DENV). Based on clustering of resistance mutations it has been assumed to target DENV non-structural protein 4B (NS4B). Using a photoaffinity labeling compound with high structural similarity to JNJ-A07, here we demonstrate binding to NS4B and its precursor NS4A-2K-NS4B. Consistently, we report recruitment of the compound to intracellular sites enriched for these proteins. We further specify the mechanism-of-action of JNJ-A07, which has virtually no effect on viral polyprotein cleavage, but targets the interaction between the NS2B/NS3 protease/helicase complex and the NS4A-2K-NS4B cleavage intermediate. This interaction is functionally linked to de novo formation of vesicle packets (VPs), the sites of DENV RNA replication. JNJ-A07 blocks VPs biogenesis with little effect on established ones. A similar mechanism-of-action was found for another NS4B inhibitor, NITD-688. In summary, we unravel the antiviral mechanism of these NS4B-targeting molecules and show how DENV employs a short-lived cleavage intermediate to carry out an early step of the viral life cycle.

Identifiants

pubmed: 39030239
doi: 10.1038/s41467-024-50437-3
pii: 10.1038/s41467-024-50437-3
doi:

Substances chimiques

Viral Nonstructural Proteins 0
Antiviral Agents 0
RNA Helicases EC 3.6.4.13
Serine Endopeptidases EC 3.4.21.-
NS4B protein, Dengue virus 0
NS4A protein, Dengue virus 0
NS2B protein, flavivirus 0
NS3 protein, flavivirus 0
NS3 protease, dengue virus EC 3.4.21.-
nonstructural protein 2B, Dengue virus 0
(+)-4-(3-((1-(4-chlorophenyl)-2-oxo2-(6-(trifluoromethoxy)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid 0
Viral Proteases EC 3.4.-
Aminophenols 0
Membrane Proteins 0
Indoles 0
DEAD-box RNA Helicases EC 3.6.4.13
Nucleoside-Triphosphatase EC 3.6.1.15
Butyrates 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6080

Subventions

Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : SFB 1129 project number 240245660
Organisme : Wellcome Trust (Wellcome)
ID : 106327/Z/14
Organisme : Wellcome Trust (Wellcome)
ID : 089328/Z/09
Organisme : Agentschap Innoveren en Ondernemen (Flanders Innovation & Entrepreneurship)
ID : IWT 150863
Organisme : Agentschap Innoveren en Ondernemen (Flanders Innovation & Entrepreneurship)
ID : IWT 150863
Organisme : Wellcome Trust (Wellcome)
ID : 106327/Z/14
Organisme : Wellcome Trust (Wellcome)
ID : 089328/Z/09

Informations de copyright

© 2024. The Author(s).

Références

Ferreira-de-Lima, V. H. & Lima-Camara, T. N. Natural vertical transmission of dengue virus in Aedes aegypti and Aedes albopictus: a systematic review. Parasit. Vectors 11, 77 (2018).
pubmed: 29391071 pmcid: 5793400 doi: 10.1186/s13071-018-2643-9
Murray, N. E. A., Quam, M. B. & Wilder-Smith, A. Epidemiology of dengue: past, present and future prospects. Clin. Epidemiol. 5, 299 (2013).
pubmed: 23990732 pmcid: 3753061
Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504–507 (2013).
pubmed: 23563266 pmcid: 3651993 doi: 10.1038/nature12060
Wilder-Smith, A., Ooi, E.-E., Horstick, O. & Wills, B. Dengue. Lancet 393, 350–363 (2019).
pubmed: 30696575 doi: 10.1016/S0140-6736(18)32560-1
Calisher, C. H. et al. Antigenic Relationships between Flaviviruses as Determined by Cross-neutralization Tests with Polyclonal Antisera. J. Gen. Virol. 70, 37–43 (1989).
pubmed: 2543738 doi: 10.1099/0022-1317-70-1-37
Halstead, S. B. Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J. Biol. Med 42, 350–362 (1970).
pubmed: 5419208 pmcid: 2591710
Chan, C. Y. et al. Antibody-Dependent dengue virus entry modulates cell intrinsic responses for enhanced infection. Msphere 4, e00528–00519 (2019).
pubmed: 31533998 pmcid: 6751492 doi: 10.1128/mSphere.00528-19
Katzelnick, L. C. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 358, 929–932 (2017).
pubmed: 29097492 pmcid: 5858873 doi: 10.1126/science.aan6836
Gebhard, L. G., Filomatori, C. V. & Gamarnik, A. V. Functional RNA elements in the dengue virus genome. Viruses 3, 1739–1756 (2011).
pubmed: 21994804 pmcid: 3187688 doi: 10.3390/v3091739
Neufeldt, C. J., Cortese, M., Acosta, E. G. & Bartenschlager, R. Rewiring cellular networks by members of the Flaviviridae family. Nat. Rev. Microbiol. 16, 125–142 (2018).
pubmed: 29430005 pmcid: 7097628 doi: 10.1038/nrmicro.2017.170
Lobigs, M., Lee, E., Ng, M. L., Pavy, M. & Lobigs, P. A flavivirus signal peptide balances the catalytic activity of two proteases and thereby facilitates virus morphogenesis. Virology 401, 80–89 (2010).
pubmed: 20207389 doi: 10.1016/j.virol.2010.02.008
Stocks, C. & Lobigs, M. Signal peptidase cleavage at the flavivirus C-prM junction: dependence on the viral NS2B-3 protease for efficient processing requires determinants in C, the signal peptide, and prM. J. Virol. 72, 2141–2149 (1998).
pubmed: 9499070 pmcid: 109509 doi: 10.1128/JVI.72.3.2141-2149.1998
Cahour, A., Falgout, B. & Lai, C. Cleavage of the dengue virus polyprotein at the NS3/NS4A and NS4B/NS5 junctions is mediated by viral protease NS2B-NS3, whereas NS4A/NS4B may be processed by a cellular protease. J. Virol. 66, 1535–1542 (1992).
pubmed: 1531368 pmcid: 240879 doi: 10.1128/jvi.66.3.1535-1542.1992
Niyomrattanakit, P. et al. Identification of residues in the dengue virus type 2 NS2B cofactor that are critical for NS3 protease activation. J. Virol. 78, 13708–13716 (2004).
pubmed: 15564480 pmcid: 533897 doi: 10.1128/JVI.78.24.13708-13716.2004
El Sahili, A. & Lescar, J. Dengue virus non-structural protein 5. Viruses 9, 91 (2017).
pubmed: 28441781 pmcid: 5408697 doi: 10.3390/v9040091
Chang, D. C. et al. Evasion of early innate immune response by 2′-O-methylation of dengue genomic RNA. Virology 499, 259–266 (2016).
pubmed: 27716465 doi: 10.1016/j.virol.2016.09.022
Zhou, Y. et al. Structure and function of flavivirus NS5 methyltransferase. J. Virol. 81, 3891–3903 (2007).
pubmed: 17267492 pmcid: 1866096 doi: 10.1128/JVI.02704-06
Płaszczyca, A. et al. A novel interaction between dengue virus nonstructural protein 1 and the NS4A-2K-4B precursor is required for viral RNA replication but not for formation of the membranous replication organelle. PLoS Pathog. 15, e1007736 (2019).
pubmed: 31071189 pmcid: 6508626 doi: 10.1371/journal.ppat.1007736
Chambers, T. J., McCourt, D. W. & Rice, C. M. Production of yellow fever virus proteins in infected cells: identification of discrete polyprotein species and analysis of cleavage kinetics using region-specific polyclonal antisera. Virology 177, 159–174 (1990).
pubmed: 2353452 doi: 10.1016/0042-6822(90)90470-C
Zhang, L., Mohan, P. M. & Padmanabhan, R. Processing and localization of Dengue virus type 2 polyprotein precursor NS3-NS4A-NS4B-NS5. J. Virol. 66, 7549–7554 (1992).
pubmed: 1433530 pmcid: 240467 doi: 10.1128/jvi.66.12.7549-7554.1992
Chatel-Chaix, L. et al. A combined genetic-proteomic approach identifies residues within Dengue virus NS4B critical for interaction with NS3 and viral replication. J. Virol. 89, 7170–7186 (2015).
pubmed: 25926641 pmcid: 4473547 doi: 10.1128/JVI.00867-15
Lin, C., Amberg, S. M., Chambers, T. J. & Rice, C. M. Cleavage at a novel site in the NS4A region by the yellow fever virus NS2B-3 proteinase is a prerequisite for processing at the downstream 4A/4B signalase site. J. Virol. 67, 2327–2335 (1993).
pubmed: 8445732 pmcid: 240389 doi: 10.1128/jvi.67.4.2327-2335.1993
Roosendaal, J., Westaway, E. G., Khromykh, A. & Mackenzie, J. M. Regulated cleavages at the West Nile virus NS4A-2K-NS4B junctions play a major role in rearranging cytoplasmic membranes and Golgi trafficking of the NS4A protein. J. Virol. 80, 4623–4632 (2006).
pubmed: 16611922 pmcid: 1472005 doi: 10.1128/JVI.80.9.4623-4632.2006
Naik, N. G. & Wu, H.-N. Mutation of putative N-glycosylation sites on dengue virus NS4B decreases RNA replication. J. Virol. 89, 6746–6760 (2015).
pubmed: 25878113 pmcid: 4468497 doi: 10.1128/JVI.00423-15
Zou, J. et al. Dimerization of flavivirus NS4B protein. J. Virol. 88, 3379–3391 (2014).
pubmed: 24390334 pmcid: 3957939 doi: 10.1128/JVI.02782-13
Munoz-Jordán, J. L. et al. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J. Virol. 79, 8004–8013 (2005).
pubmed: 15956546 pmcid: 1143737 doi: 10.1128/JVI.79.13.8004-8013.2005
Arakawa, M. et al. Flavivirus recruits the valosin-containing protein–NPL4 complex to induce stress granule disassembly for efficient viral genome replication. J. Biol. Chem. 298, 101597 (2022).
Zou, J. et al. Mapping the interactions between the NS4B and NS3 proteins of dengue virus. J. Virol. 89, 3471–3483 (2015).
pubmed: 25589636 pmcid: 4403433 doi: 10.1128/JVI.03454-14
Zou, J. et al. Characterization of dengue virus NS4A and NS4B protein interaction. J. Virol. 89, 3455–3470 (2015).
pubmed: 25568208 pmcid: 4403404 doi: 10.1128/JVI.03453-14
Umareddy, I., Chao, A., Sampath, A., Gu, F. & Vasudevan, S. G. Dengue virus NS4B interacts with NS3 and dissociates it from single-stranded RNA. J. Gen. Virol. 87, 2605–2614 (2006).
pubmed: 16894199 doi: 10.1099/vir.0.81844-0
Lu, H. et al. Novel insights into the function of an N-terminal region of DENV2 NS4B for the optimal helicase activity of NS3. Virus Res. 295, 198318 (2021).
pubmed: 33485995 doi: 10.1016/j.virusres.2021.198318
Welsch, S. et al. Composition and three-dimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe 5, 365–375 (2009).
pubmed: 19380115 pmcid: 7103389 doi: 10.1016/j.chom.2009.03.007
Ng, M. L. Ultrastructural studies of Kunjin virus-infected Aedes albopictus cells. J. Gen. Virol. 68, 577–582 (1987).
pubmed: 3029292 doi: 10.1099/0022-1317-68-2-577
Cerikan, B. et al. A non-replicative role of the 3′ terminal sequence of the dengue virus genome in membranous replication organelle formation. Cell Rep. 32, 107859 (2020).
pubmed: 32640225 pmcid: 7351112 doi: 10.1016/j.celrep.2020.107859
Paul, D. & Bartenschlager, R. Flaviviridae replication organelles: oh, what a tangled web we weave. Annu Rev. Virol. 2, 289–310 (2015).
pubmed: 26958917 doi: 10.1146/annurev-virology-100114-055007
Junjhon, J. et al. Ultrastructural characterization and three-dimensional architecture of replication sites in dengue virus-infected mosquito cells. J. Virol. 88, 4687–4697 (2014).
pubmed: 24522909 pmcid: 3993787 doi: 10.1128/JVI.00118-14
Kaptein, S. J. F. et al. A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction. Nature 598, 504–509 (2021).
pubmed: 34616043 doi: 10.1038/s41586-021-03990-6
Kesteleyn, B. et al. Discovery of JNJ-1802, a First-in-Class Pan-Serotype Dengue Virus NS4B Inhibitor. J. Med. Chem. 67, 4063–4082 (2024).
Goethals, O. et al. Blocking NS3–NS4B interaction inhibits dengue virus in non-human primates. Nature 615, 678–686 (2023).
pubmed: 36922586 pmcid: 10033419 doi: 10.1038/s41586-023-05790-6
Gao, Z. et al. A yellow fever virus NS4B inhibitor not only suppresses viral replication, but also enhances the virus activation of RIG-I-like receptor-mediated innate immune response. PLoS Pathog. 18, e1010271 (2022).
pubmed: 35061864 pmcid: 8809586 doi: 10.1371/journal.ppat.1010271
Moquin, S. A. et al. NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models. Sci. Transl. Med. 13, eabb2181 (2021).
pubmed: 33536278 doi: 10.1126/scitranslmed.abb2181
Smith, E. & Collins, I. Photoaffinity labeling in target-and binding-site identification. Future Med. Chem. 7, 159–183 (2015).
pubmed: 25686004 doi: 10.4155/fmc.14.152
Miller, S., Sparacio, S. & Bartenschlager, R. Subcellular localization and membrane topology of the dengue virus type 2 non-structural protein 4B. J. Biol. Chem. 281, 8854–8863 (2006).
pubmed: 16436383 doi: 10.1074/jbc.M512697200
Behnam, M. A. & Klein, C. D. Corona versus Dengue: Distinct Mechanisms for Inhibition of Polyprotein Processing by Antiviral Drugs. ACS Pharmacol. Transl. Sci. 5, 508–511 (2022).
pubmed: 35837137 pmcid: 9274768 doi: 10.1021/acsptsci.2c00105
Falgout, B., Pethel, M., Zhang, Y.-M. & Lai, C. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J. Virol. 65, 2467–2475 (1991).
pubmed: 2016768 pmcid: 240601 doi: 10.1128/jvi.65.5.2467-2475.1991
Guo, F. et al. A novel benzodiazepine compound inhibits yellow fever virus infection by specifically targeting NS4B protein. J. Virol. 90, 10774–10788 (2016).
pubmed: 27654301 pmcid: 5110185 doi: 10.1128/JVI.01253-16
Gao, M. et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96–100 (2010).
pubmed: 20410884 pmcid: 7094952 doi: 10.1038/nature08960
Bartenschlager, R., Ahlborn-Laake, L., Mous, J. & Jacobsen, H. Kinetic and structural analyses of hepatitis C virus polyprotein processing. J. Virol. 68, 5045–5055 (1994).
pubmed: 8035505 pmcid: 236447 doi: 10.1128/jvi.68.8.5045-5055.1994
Berger, C. et al. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus–induced membranous replication factories, independent of RNA replication. Gastroenterology 147, 1094–1105. e1025 (2014).
pubmed: 25046163 doi: 10.1053/j.gastro.2014.07.019
Kesteleyn, B. R. R., Raboisson, P. J.-M. B., Bonfanti, J.-F., Bardiot, D. A. M.-E. & Marchand, A. D. M. Substituted indoline derivatives as dengue viral replication inhibitors. Patent WO/2017/167951 (2017).
Goellner, S. et al. Replication-Independent Generation and Morphological Analysis of Flavivirus Replication Organelles. STAR Protoc. 1, 100173 (2020).
pubmed: 33377067 pmcid: 7757399 doi: 10.1016/j.xpro.2020.100173
David, A. et al. Nuclear translation visualized by ribosome-bound nascent chain puromycylation. J. Cell Biol. 197, 45–57 (2012).
pubmed: 22472439 pmcid: 3317795 doi: 10.1083/jcb.201112145

Auteurs

Dominik Kiemel (D)

Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Disease Research, Heidelberg, Germany.

Ann-Sophie Helene Kroell (AH)

Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Disease Research, Heidelberg, Germany.

Solène Denolly (S)

Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Disease Research, Heidelberg, Germany.

Uta Haselmann (U)

Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Disease Research, Heidelberg, Germany.

Jean-François Bonfanti (JF)

Janssen Infectious Diseases Discovery, Janssen-Cilag, Val de Reuil, France.
Evotec, Toulouse, France.

Jose Ignacio Andres (JI)

Discovery Chemistry, Janssen R&D, a Johnson & Johnson company, Toledo, Spain.

Brahma Ghosh (B)

Discovery Chemistry, Janssen R&D, a Johnson & Johnson company, Spring House, PA, USA.

Peggy Geluykens (P)

Discovery, Charles River Beerse, Beerse, Belgium.

Suzanne J F Kaptein (SJF)

Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.

Lucas Wilken (L)

Leibniz Institute of Virology, Hamburg, Germany.

Pietro Scaturro (P)

Leibniz Institute of Virology, Hamburg, Germany.

Johan Neyts (J)

Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.

Marnix Van Loock (M)

Janssen Global Public Health, Janssen Pharmaceutica NV, a Johnson & Johnson company, Beerse, Belgium.

Olivia Goethals (O)

Janssen Global Public Health, Janssen Pharmaceutica NV, a Johnson & Johnson company, Beerse, Belgium.

Ralf Bartenschlager (R)

Heidelberg University, Medical Faculty Heidelberg, Department of Infectious Diseases, Molecular Virology, Center for Integrative Infectious Disease Research, Heidelberg, Germany. ralf.bartenschlager@med.uni-heidelberg.de.
German Centre for Infection Research, Heidelberg partner site, Heidelberg, Germany. ralf.bartenschlager@med.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH